Study authors examined the risk for admission and respiratory failure in patients with rheumatic disorders with COVID-19 receiving DMARDs or methotrexate.
A deeper insight into the association between treatment with biologic disease-modifying antirheumatic drugs in rheumatic diseases and risk for type 2 diabetes.
Upadacitinib is superior to abatacept for patients with rheumatoid arthritis refractory to biologic DMARDs.
An overview of the comparative effectiveness of biologic medications in rheumatoid arthritis.
Researchers evaluated the efficacy of biologic disease-modifying antirheumatic drugs in achieving remission in axial spondyloarthritis.
Researchers assessed the association between dysregulated central pain processing and treatment response in rheumatoid arthritis.
Researchers evaluated the risk for COVID-19 infection and its severity in patients receiving DMARDs.
Researchers compared the incidence and severity of COVID-19 in patients with rheumatic disease receiving DMARDs and the general population.
Researchers evaluated the effectiveness and timing of DMARDs in the treatment of chil-dren with newly diagnosed polyarticular course juvenile idiopathic arthritis.
For older patients with rheumatoid arthritis (RA), there is considerable variation in time to receipt of first biologic disease-modifying antirheumatic drug (DMARD) after prescription of the first conventional synthetic (cs) DMARD.
